Please assess the completion status of the following clinical trial:

Trial Title: Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Participants meeting the following eligibility criteria were enrolled.~Inclusion criteria:~1. Male participants \[3 years to \<= 9 years + 0 days old\] at Visit 1 and no older than \[9 years + 120 days\] at Visit 3; and, female participants \[3 years to \<= 8 years + 0 days old\] at Visit 1 and no older than \[8 years + 120 days\] at Visit 3: all sexually prepubertal (ie, Stage 1 of Tanner Classification of sexual maturity) at Visit 1 and Visit 3. A 5-day extension to the age upper bound was permitted under certain circumstances to enable scheduling of Visits 1 and 3~2. At least a one year history of PAR as assessed and documented by the investigator (with or without seasonal allergic rhinitis \[SAR\])~3. Positive skin test (prick or intradermal) to a perennial allergen that was present in the participant's environment. A skin test was considered positive if the wheal produced by the allergen was equal to or greater than that caused by positive control (histamine) or was at least 3 mm (prick test) or 7 mm (intradermal test) greater than the wheal of negative control (saline). If a skin test could not be performed, the radioallergosorbent test (RAST) would be used as an alternative. Documented historical skin testing or RAST performed during the past year were acceptable~4. Height within the 3rd and 97th percentiles at screening (Visit 1), Visit 2, and at randomization (Visit 3)~5. Symptomatic (daily AM instantaneous total nasal symptom score was \>= 4 out of 12) on any 4 out of the last 7 consecutive days immediately prior to and including the morning of Visit 3. Symptom ratings were to be completed with the help of a parent/guardian/caregiver~6. Written informed consent and ability of parent or legal guardian of the participant to give a written informed consent before any study related procedures. Participants 7 years of age and older must have provided a signed assent form~7. Participants had to be toilet-trained~Exclusion criteria:~1. Gross nasal anatomical deformities including large polyposis and marked deviated septum~2. History of or current cataract or glaucoma~3. History of hypersensitivity to the corticosteroids or to any excipient of the investigational product~4. Participant was the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol~5. Height, weight, or body mass index (BMI)-for-age below the 3rd or above the 97th percentile at Visits 1, 2, or 3~6. Treatment with systemic corticosteroids (oral, intravenous, intramuscular, or intra-articular) within 3 months prior to Visit 1~7. Treatment with systemic corticosteroids for \>2 courses received up to 1 year before Visit 1 was exclusionary. Up to 2 courses of systemic corticosteroids each course not exceeding 14 days up to 1 year before Visit 1 was allowed.~8. Treatment with inhaled, intranasal, or high potency topical corticosteroid exposure within 6 weeks prior to Visit 1. Mild asthma that was well-controlled and without the use of inhaled corticosteroids within 6 weeks before screening (Visit 1).~9. Immunotherapy, except stable (\>=1 month) maintenance schedule before Visit 1.~10. Treatment with any substance before Visit 1 that might have affected growth velocity and/or linear growth, such as, but not be limited to methylphenidate hydrochloride, thyroid hormone, growth hormone, anabolic steroids, calcitonin, estrogens, progestins, bisphosphonates, anticonvulsants, or phosphate-binding antacids~11. Treatment with any investigational product or device in the 30 days before Visit 1 or at any time throughout the duration of this trial (Visit 1 through Visit 11).~12. Bone age as assessed by X-ray of the left hand and wrist that was outside +/- 1.5 years of participants chronological age at Visit 2. Right hand and wrist were to be radiographed in the event of bone injury to the left hand or wrist.~13. Unresolved upper respiratory tract infection, sinus infection or nasal candidiasis (i.e., symptomatic or under treatment) within the last 2 weeks before Visit 3.~14. Participants or parent/guardian/caregiver unable to demonstrate correct administration of the investigational product at Visit 1.~15. Concomitant disease other than PAR which could have interfered with the study procedures or outcomes as determined by the investigator.~16. History of hospitalization due to asthma within 1 year before screening (Visit 1).~17. Abnormal 24-hour urinary free cortisol level assessed at screening (Visit 2).~The above information was not intended to contain all considerations relevant to potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 9 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 3 to 9 year old participants with Perennial Allergic Rhinitis (PAR) administered~* Placebo in the baseline/screening period to demonstrate administration of investigational product (IP) with the nasal spray bottle~* Placebo in the double-blind treatment period~All participants were provided Children's Claritin® Syrup as a rescue medication.
- TAA-AQ (Type: ACTIVE_COMPARATOR): 3 to 9 year old participants with Perennial Allergic Rhinitis (PAR) administered~* Placebo in the baseline/screening period to demonstrate administration of IP with the nasal spray bottle~* Triamcinolone acetonide (TAA-AQ) in the double-blind treatment period~All participants were provided Children's Claritin® Syrup as a rescue medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).